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A B S T R A C T
Status epilepticus (SE) is a neurological emergency associated with a high morbidity and mortality. A
prospective 3-year study was conducted in our hospital on 56 consecutive inpatients with SE.
Demographic and clinical data were collected. EEG and clinical SE features were considered for the SE
classiﬁcation, both separately and together. The etiology of SE was determined. Patients were treated
according to international standardized protocols of guidelines for the management of epilepsy.
Response to treatment was evaluated clinically and electrophysiologically. Outcome at 30 days was
considered as good, poor or death. Convulsive SE (CSE) was observed in 35 patients and non-convulsive
SE (NCSE) in 21. Patients with CSE, in particular focal-CSE, were older than those with NCSE. As regards
etiology, patients with SE secondary to cerebral lesions were the oldest, followed by patients with anoxic
SE and those with toxic dysmetabolic SE. A ﬁrst-line treatment was usually sufﬁcient to control seizure
activity in lesional and epileptic SE, while more aggressive treatment was necessary in all anoxic SE
patients. Outcome was good in 35 patients, poor in 12, while 9 died. A prompt neurophysiological EEG
evaluation, combined with the clinical evaluation, helps to make a rapid prognosis and take therapeutic
management decisions. First-line treatments may be sufﬁcient to control electro-clinical status in
lesional and epileptic SE, while intensive care unit management, a more aggressive therapeutic approach
and continuous EEG monitoring are recommended for refractory SE.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Status epilepticus (SE) is a neurological emergency associated
with a high morbidity and mortality.1 In industrialized countries
with Caucasian populations, the incidence of SE ranges from 9.9 to
41/100,000/year,2–6 with a higher incidence in patients older than
60 years (54–86/100,000/year); this high variability is partially
related to the different criteria used to diagnose SE.7–9 According to
Shorvon,10 one of the most complete deﬁnitions of SE, based on
both clinical and neurophysiological ﬁndings, is: ‘‘a condition in
which epileptic activity persists for 30 minutes or more, causing a
wide spectrum of clinical symptoms and with a highly variable
pathophysiological, anatomical and aetiological basis’’. Hospitali-
zation, accompanied by both clinical and neurophysiological
investigations, of patients suspected of having SE is thus warranted* Corresponding author at: Neurophysiopathology Emergency Unit, Department
of Neurology and Psychiatry, Sapienza University of Rome, Viale Regina Elena 336,
00185 Rome, Italy. Tel.: +39 06 49912875; fax: +39 06 49912657.
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doi:10.1016/j.seizure.2011.09.010to promptly diagnose this condition and provide optimal
management.9
According to the electro-clinical features, SE is commonly
classiﬁed as convulsive (CSE), non-convulsive (NCSE), generalized
(SE-G) or focal (SE-F).11 Moreover, the term NCSE is used in the
literature to refer to both generalized SE and complex partial SE.
The neurophysiological EEG evaluation, which demonstrates
ongoing ictal activity, is fundamental to identify cases of unknown
origin.12 The exact diagnosis of each SE type is not only needed to
guide treatment choices,13 but also to evaluate the response to
therapy and to correlate SE outcome with the prognostic factors.
The SE mortality rate is approximately 20%, with most patients
dying as a result of the underlying condition (such as stroke),
rather than of the status epilepticus itself.14 Indeed, while 52% of SE
cases in children are secondary to infections with fever, in adults
the main causes of acute SE are an insufﬁcient dosage of
antiepileptic drugs, cerebrovascular events, hypoxia, metabolic
causes and alcohol intoxication. Prognostic indicators of poorer
outcome include older age and acute symptomatic etiology.15
Results are less consistent for other variables, such as time-to-
treatment or to seizure control and gender.16 Rossetti et al.17vier Ltd. All rights reserved.
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STESS) based on four outcome predictors determined before
administration of treatment: age with a 65-year cut-off, previous
history of seizures, seizure type and extent of consciousness
impairment. A scrupulous evaluation of SE outcome predictors
might help to select the most appropriate treatment strategies for
each patient. SE treatment protocols recommend a wide range of
drug intensities, including small doses of benzodiazepines,
combinations of intravenously administered antiepileptic drugs
and coma-induction with appropriate anesthetic agents.18 In 2006,
a SE subcommission of the Guidelines Commission of the Italian
League against Epilepsy drew up the guidelines for the manage-
ment of SE in adults.9 Although all the guidelines refer to
convulsive, tonic–clonic generalized SE management, they may
be extended to the treatment of every type of SE in clinical practice.
The aim of this study is to provide a report of a 3-year study on
the diagnosis and management of SE, conducted in our university
hospital, based on an analysis of the patients’ demographic data, SE
type, response to AED treatment and outcome.
2. Materials and methods
We conducted a 3-year prospective study for which we enrolled
consecutive adult inpatients at the Policlinico Umberto I Hospital
(Sapienza University of Rome), between January 1st 2007 and
December 31st 2009. All the patients, who had been admitted to
the emergency room or were already hospitalized in other medical
and surgical divisions, were diagnosed as having SE, according to
the clinical presentation and EEG ﬁndings. Our laboratory is the
only emergency EEG Service at the Policlinico Umberto I University
Hospital that is open 6 days a week, 12 hours a day. The hospital,
which is located in the centre of Rome, has a secondary level
emergency department to which patients with suspected neuro-
logical emergency conditions are electively transferred from the
surrounding areas. Exclusion criteria were: patients < 18 years
old; patients admitted overnight or on Sundays and treated for SE
without an EEG recording. Patients received the best clinical
treatment for the underlying disease, while the instrumental
diagnosis included cerebral neuroimaging with CT or MRI.
2.1. EEG execution
An EEG with electro-cardiography (ECG) and electromyography
(EMG) was performed with a digital apparatus (Micromed, Italy) and
sampled at rate of 256 Hz. The following conventional chloride disc
electrodes were applied on the scalp, according to the International
10-20 System: Fp2, Fp1, T4, T3, C4, C3, O2 and O1. After SE was
diagnosed, the EEG recording was continued throughout the
pharmacological treatment and for at least 30 min after resolution
of the SE. In patients in whom the SE did not resolve, the EEG was
performed again daily or upon request for clinical reasons.
2.2. SE antiepileptic treatment
According to the Italian guidelines for SE management,9
treatment was administered using 4 standardized protocols, applied
successively according to temporal parameters and the patient’s
response to AED drugs; each subsequent protocol was only applied if
the previous protocol proved unsuccessful. The temporal param-
eters were: initial SE (within 30 min), established SE (within 90 min)
and refractory SE (after 90 min). Protocol 1 for initial SE was based on
lorazepam (0.05–0.1 mg/kg i.v. – maximum infusion rate 2 mg/min)
or diazepam (0.1 mg/kg/i.v. – in 60 s). Protocol 2 for established SE
was based on phenytoin (15–18 mg/kg i.v. at a maximum infusion
rate of 50 mg/min). Protocol 3 for refractory SE was based on
thiopental (5–7 mg/kg i.v. in 20 s followed by boluses at intervals of2–3 min) or propofol (2–5 mg/kg i.v. bolus followed by continuous
infusion up to 5 mg/kg/h). Administration of thiopental or propofol
required the assistance of an anesthesiologist. Protocol 4, which was
reserved for alternative therapies when previous drugs were
ineffective or contraindicated, was based on sodium valproate
(15 mg/kg i.v. over 5 min followed by 1–2 mg/kg/h as a continuous
infusion, depending on the clinical response), midazolam (0.1–
0.3 mg/kg as i.v. bolus, at a maximum infusion rate of 4 mg/min) and
phenobarbital (10–20 mg/kg i.v. infused over 10 min – 50–75 mg/
min). From 2008 onwards, intravenously administered levetirace-
tam (20 mg/kg i.v. infused over 15 min) was also used.19
To assess the response to therapy, EEG monitoring was
performed throughout AED treatment in order to follow cortical
electrical activity modiﬁcations, as well as for at least one hour after
seizure activity cessation. We considered the treatment effective
when the complete resolution of epileptic discharges was observed
and persisted for at least 30 min after the end of treatment. Since
patients were hospitalized in the Intensive Care Unit or other
emergency departments, subsequent neurophysiological testing
was performed daily or upon request for clinical reasons.
2.3. SE classiﬁcation
The following data were analysed in all the patients: (1)
demographic data (age, sex), with age being considered both by
adopting a cut-off of 65 years, as generally reported in the literature,
and as a continuous variable; (2) SE clinical type: convulsive (CSE)
and non-convulsive (NCSE), according to the clinical neurological
presentation (presence of focal neurological symptoms – i.e. positive
or negative–, localized or diffuse movement disorders – i.e. clonic,
tonic–clonic or myoclonia–, eyelid myoclonia, lack of response to
simple commands, autonomic dysfunction and cognitive/conscious-
ness alterations); (3) SE EEG features: focal (F-SE) or generalized (G-
SE) epileptic discharges; (4) electro-clinical correlations, consider-
ing both points (2) and (3): non-convulsive focal and generalized SE
(NCSE-F, NCSE-G), convulsive focal or generalized SE (CSE-F, CSE-G);
(5) etiology of SE according to instrumental ﬁndings, neuroimaging
study (cerebral CT and/or MRI scan) and/or blood examinations and
classiﬁed as: (a) lesional SE, (b) primary epileptic SE, (c) toxic
metabolic SE or (d) anoxic SE; (6) response to antiepileptic treatment
protocols 1, 2, 3 or 4; (7) clinical outcome after 30 days as: (a) good
(return to normal daily activities), (b) poor (persistence of
neurological deﬁcit) and (c) death.
2.4. Statistical analysis
Data are presented in raw numbers. Data were analysed using
SPSS 16 for Macintosh. x2 and cross tabulation tables were used to
compare differences in categorical variables. Student’s t-test and
ANOVA were used to determine differences between continuous
variables in the categorical classes. Post-hoc analysis with
Bonferroni’s correction and Scheffe` tests were used to determine
multiple comparisons. Statistical signiﬁcance was set at p < 0.05.
3. Results
Over a period of 3 years, we identiﬁed 56 patients with SE, 29 of
whom were men and 27 women, with a mean age of 64.05  20.4
years. The EEG was performed within 3.5  2.8 h of the primary care
physician’s request. A full description of the population enrolled is
provided in Table 1.
3.1. ClinicalSEtype(CSE/NCSE)and EEGSEtype(F-SE/G-SE):ageand sex
As regards the clinical SE type, convulsive status epilepticus was
observed in 35/56 patients and non-convulsive status epilepticus
Table 1
Complete description of SE population.
Patient Sex Age SE type SE pathophysiology Therapy Outcome
Clinical SE EEG SE Electro-clinical SE SE description Etiology Neuroimaging ﬁndings
1 F 65 CSE F-SE CSE-F SPSE-motor Lesional Neoplasia Protocol-1 Good
2 M 77 NCSE F-SE NCSE-F CPSE Lesional Ischemia Protocol-1 Good
3 M 73 CSE F-SE CSE-F SPSE-disphasic Lesional Hemorrhage Protocol-1 Poor
4 M 72 CSE F-SE CSE-F SPSE-motor Lesional Ischemia Protocol-2 Good
5 M 84 CSE F-SE CSE-F SGCSE Lesional Subdural hemorrhage Protocol-4 Death
6 F 65 CSE F-SE CSE-F SPSE-motor Lesional Ischemia Protocol-1 Good
7 M 36 NCSE G-SE NCSE-G ASE Epileptic (IGE) Normal Protocol-1 Good
8 F 46 NCSE F-SE NCSE-F CPSE Lesional Herpetic encephalitis Protocol-1 Good
9 M 56 CSE F-SE CSE-F PGCSE Epileptic (IGE) Normal Protocol-1 Good
10 M 43 CSE G-SE CSE-G GMSE Epileptic (CGE) Normal Protocol-1 Good
11 M 18 NCSE G-SE NCSE-G ASE-ME Epileptic (IGE) Normal Protocol-1 Good
12 M 48 NCSE F-SE NCSE-F CPSE Lesional Subdural hemorrhage Protocol-1 Good
13 F 20 NCSE G-SE NCSE-G AASE Epileptic (LGS) Normal Protocol-1 Good
14 F 81 CSE F-SE CSE-F SPSE-motor Lesional Subdural hemorrhage Protocol-1 Poor
15 M 61 CSE F-SE CSE-F SPSE-motor Lesional Ischemia Protocol-1 Good
16 F 91 CSE F-SE CSE-F SPSE-motor Lesional Ischemia Protocol-1 Death
17 M 19 CSE F-SE CSE-F PGCSE Epileptic (IGE) Normal Protocol-1 Good
18 F 67 CSE G-SE CSE-G GMSE Anoxic Normal Protocol-3 Death
19 M 83 NCSE F-SE NCSE-F CPSE Lesional Venous thrombosis Protocol-1 Good
20 F 76 CSE G-SE CSE-G GMSE Anoxic Normal Protocol-3 Death
21 M 56 CSE F-SE CSE-F SPSE-motor Lesional Neoplasia Protocol-1 Good
22 F 85 CSE F-SE CSE-F SPSE-motor Lesional Ischemia Protocol-2 Poor
23 M 52 CSE F-SE CSE-F SPSE-disphasic Metabolic (NKH) Normal Protocol-1 Good
24 F 59 CSE F-SE CSE-F SPSE-motor Lesional Subdural hemorrhage Protocol-1 Good
25 F 86 CSE F-SE CSE-F SPSE-motor Lesional Subdural hemorrhage Protocol-1 Good
26 M 71 NCSE F-SE NCSE-F CPSE Lesional Ischemia Protocol-2 Good
27 M 62 CSE F-SE CSE-F SGCSE Lesional Ischemia Protocol-3 Poor
28 M 54 CSE F-SE CSE-F SPSE-motor Lesional Ischemia Protocol-1 Good
29 M 89 CSE F-SE CSE-F SPSE-motor Lesional Ischemia Protocol-1 Poor
30 F 61 NCSE F-SE NCSE-F CPSE Lesional Cerebral vasculitis Protocol-2 Good
31 M 39 NCSE G-SE NCSE-G ASE Epileptic (CGE) Normal Protocol-1 Good
32 F 89 CSE F-SE CSE-F SPSE-motor Lesional Ischemia Protocol-1 Good
33 M 88 NCSE F-SE NCSE-F CPSE Lesional Ischemia Protocol-2 Poor
34 F 86 CSE F-SE CSE-F SGCSE Lesional Subdural hemorrhage Protocol-1 Poor
35 M 67 CSE F-SE CSE-F SGCSE Lesional Ischemia Protocol-3 Good
36 M 82 CSE F-SE CSE-F SPSE-motor Lesional Subarachnoid hemorrhage Protocol-2 Good
37 F 91 NCSE F-SE NCSE-F CPSE Lesional Subdural hemorrhage Protocol-1 Good
38 F 94 CSE F-SE CSE-F SPSE-motor Lesional Subdural hemorrhage Protocol-2 Death
39 F 76 NCSE F-SE NCSE-F CPSE Lesional Capsular hemorrhage Protocol-1 Good
40 M 56 NCSE F-SE NCSE-F CPSE Lesional Hemorrhage Protocol-4 Good
41 M 66 NCSE G-SE NCSE-G ASE Epileptic (CGE) Normal Protocol-1 Good
42 M 80 CSE F-SE CSE-F SGCSE Lesional Subarachnoid hemorrhage Protocol-4 Good
43 F 22 NCSE F-SE NCSE-F CPSE Lesional Hemorrhage Protocol-4 Poor
44 F 50 CSE G-SE CSE-G GMSE Anoxic Normal Protocol-3 Death
45 F 85 CSE F-SE CSE-F SGCSE Lesional Ischemia Protocol-4 Poor
46 F 45 NCSE G-SE NCSE-G GNSE Metabolic Normal Protocol-4 Good
47 F 70 NCSE F-SE NCSE-F CPSE Lesional PRES Protocol-2 Good
48 F 83 NCSE G-SE NCSE-G ASE Epileptic (IGE) Normal Protocol-1 Good
49 F 74 NCSE G-SE NCSE-G GNSE Metabolic (SH) Normal Protocol-3 Good
50 M 67 CSE G-SE CSE-G GMSE Anoxic Normal Protocol-4 Death
51 F 62 CSE G-SE CSE-G GMSE Anoxic Normal Protocol-4 Death
52 M 59 CSE G-SE CSE-G GMSE Anoxic Normal Protocol-4 Death
53 M 40 CSE G-SE CSE-G GMSE Lesional CADASIL Protocol-4 Poor
54 F 21 NCSE F-SE NCSE-F CPSE Lesional Glioblastoma Protocol-4 Poor
55 M 57 CSE G-SE CSE-G GMSE Epileptic (IGE) Normal Protocol-1 Good
56 F 82 CSE F-SE CSE-F SPSE-motor Lesional Ischemia Protocol-2 Poor
Legend: M: male; F: female; CSE: convulsive status epilepticus; NCSE: non-convulsive status epilepticus; F-SE: focal status epilepticus; G-SE: generalized status epilepticus;
SPSE: simple partial status epilepticus; CPSE: complex partial status epilepticus; SGCSE: secondary generalized status epilepticus; PGCSE: primary generalized status
epilepticus; GMSE: generalized myoclonic status epilepticus; ASE: absence status epilepticus; ASE-ME: absence status epilepticus with myoclonic eyelid; AASE: atypical
absence status epilepticus; GNSE: generalized non-convulsive status epilepticus; IGE: idiopathic generalized epilepsy; CGE: cryptogenic generalized epilepsy; NKH: non-
ketotic hyperglycemia; PRES: posterior reversible encephalopathy syndrome; LGS: Lennox–Gastaut syndrome; CADASIL: cerebral autosomal dominant arteriopathy; SH:
severe hypothyroidism.
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difference was observed for age when the cut-off was 65 years or
gender. When age was considered as a continuous variable,
patients with CSE were found to be signiﬁcantly older than patients
with NCSE (ANOVA: F = 4.616, p = 0.036).
As regards the EEG SE type, generalized SE was observed in 17/
56 and partial SE in the remaining 39/56 patients. No differencewas observed for gender. Patients with focal SE were older, both
when a cut-off of 65 years was used (x2 = 4.75, p = 0.03) and when
age was considered as a continuous variable (ANOVA: F = 7.954,
p = 0.007).
As regards the clinical and EEG SE type taken together, no
differences were observed for sex or age when a cut-off of 65 years
was adopted. When age was instead considered as a continuous
Table 2
Type of SE (clinical, EEG and both) correlation with age and sex.
Sex (M/F) Age < 65 years Age  65 years Age (m  SD)
Clinical SE
CSE 19/16 13 22 68.46  16.8
NCSE 10/11 11 10 56.7  23.9
*
EEG SE
F-SE 20/19 13 26 68.85  19.4
G-SE 9/8 26 6 53.06  18.8
* **
Clinical + EEG SE
CSE-F 14/12 7 19 72.12  16.9
CSE-G 5/4 6 3 57.89  11.8
NCSE-F 6/7 6 7 62.31  22.9
NCSE-G 4/4 5 3 47.62  24.3
**
Legend: CSE: convulsive status epilepticus; NCSE: non-convulsive status epilepti-
cus; F-SE: focal status epilepticus; G-SE: generalized status epilepticus; CSE-F:
convulsive focal status epilepticus; CSE-G: convulsive generalized status epilepti-
cus; NCSE-F: non-convulsive focal status epilepticus; NCSE-G: non-convulsive
generalized status epilepticus.
* p < 0.05.
** p < 0.005.
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the four groups (ANOVA: F = 3.911, p = 0.014), with patients with
focal SE (CSE or NCSE) being older.
The data are summarized in Table 2.
3.2. SE etiology
Lesional SE was observed in 37/56 patients, epileptic SE in 10/
56 patients, toxic-dysmetabolic SE in 3/56 patients and anoxic SE
in 6/56 patients. No differences were observed in gender as regards
the SE etiology. A signiﬁcant difference was observed for age and SE
etiology, both when a cut-off of 65 years was adopted (x2 = 9.056,Table 3
Etiology of SE, sex, age, and SE type.
Etiology M/F Age < 65 years Age  65 years Age (m  SD)
Lesional 18/19 11 26 70.2  18.3 
Epileptic 8/2 8 2 43.7  21.8 
Toxic-dysmetabolic 1/2 2 1 57  15.1 
Anoxic 2/4 3 3 63.5  8.7 
* **
Total 29/27 24 32
Legend: CSE: convulsive status epilepticus; NCSE: non-convulsive status epilepticus; F-S
focal status epilepticus; CSE-G: convulsive generalized status epilepticus; NCSE-F: no
epilepticus.
* p < 0.05.
** p < 0.005.
Table 4
Response to treatment, SE type and etiology.
Treatment protocol Clinical SE type EEG SE type 
CSE NCSE F-SE G-S
Protocol-1 18 12 22 8 
Protocol-2 5 4 9 0 
Protocol-3 5 4 6 3 
Protocol-4 7 1 2 6 
** 
Legend: CSE: convulsive status epilepticus; NCSE: non-convulsive status epileptic
benzodiazepines; PHT: phenytoin.
** p < 0.005.p = 0.029) and when age was considered as a continuous variable
(ANOVA: F = 5.715, p = 0.002): the oldest patients were those with
lesional SE, followed by patients with anoxic SE and those with
toxic dysmetabolic SE. Patients with epileptic SE were the
youngest. Post-hoc analysis with Bonferroni’s correction showed
that the difference within groups was signiﬁcant only in lesional vs
epileptic patients (p = 0.001). The clinical and EEG data divided
according to etiology are shown in Table 3.
3.3. SE treatment
Thirty out of 56 patients displayed complete SE regression after
being treated with protocol 1, 9/56 after protocols 1 + 2, 9/56 after
protocols 1 + 2 + 3 while 8/56 needed protocol 4 to control
epileptic activity. If we consider the type of SE according to the
clinical classiﬁcation (CSE vs NCSE), no difference emerged in the
number of protocols needed to eliminate epileptic activity. If we
consider the SE according to the EEG ﬁndings (F-SE and G-SE), a
difference in response to treatment emerged, with protocol 1 most
frequently proving to be sufﬁcient to successfully treat F-SE
(x2 = 1.170, p < 0.009). As regards SE etiology, a difference in the
response to treatment was observed (x2 = 3.873, p < 0.000), with
protocol 1 most frequently proving to be sufﬁcient to successfully
treat patients with lesional and epileptic SE, while protocols 3 or 4
were needed in all anoxic patients. The data are presented in Table
4.
3.4. SE outcome
Outcome was good in 35/56 patients, poor in 12/56 patients,
while 9/56 patients died. No difference was observed for sex and
age either when a cut-off of 65 years was adopted or when age was
considered as a continuous variable, though a trend toward a
worse outcome and death did emerge in older patients. A
signiﬁcant difference was observed in outcome as regards the Clinical SE
type
EEG SE type Clinical + EEG SE type
CSE NCSE F-SE G-SE CSE-F CSE-G NCSE-F NCSE-G
24 13 36 1 23 1 13 0
4 6 2 8 2 2 0 6
1 2 1 2 1 0 0 2
6 0 0 6 0 6 0 0
E: focal status epilepticus; G-SE: generalized status epilepticus; CSE-F: convulsive
n-convulsive focal status epilepticus; NCSE-G: non-convulsive generalized status
SE etiology
E Lesional Epileptic Toxic Anoxic
19 10 1 0
9 0 0 0
7 0 1 1
2 0 1 5
**
us; F-SE: focal status epilepticus; G-SE: generalized status epilepticus; BDZ:
Table 5
SE outcome, demographic CSE type and etiology.
Outcome M/F Age < 65 years Age  65 years Age (m  SD) Clinical SE type EEG SE type Clinical + EEG SE type
CSE NCSE F-SE G-SE CSE-F CSE-G NCSE-F NCSE-G
Good 21/14 17 18 60.6  19.3 17 18 25 10 15 2 10 8
Poor 5/7 4 8 67.8  25.7 9 3 11 1 8 1 3 0
Dead 3/6 3 6 72.2  15 9 0 3 6 3 6 0 0
* * **
Legend: CSE: convulsive status epilepticus; NCSE: non-convulsive status epilepticus; F-SE: focal status epilepticus; G-SE: generalized status epilepticus; CSE-F: convulsive
focal status epilepticus; CSE-G: convulsive generalized status epilepticus; NCSE-F: non-convulsive focal status epilepticus; NCSE-G: non-convulsive generalized status
epilepticus.
* p < 0.05.
** p < 0.005.
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p < 0.015) and both (x2 = 2.594, p < 0.000), with a better outcome
emerging in CSE, F-SE and CSE-F. The data are shown in Table 5.
A signiﬁcant difference was observed in outcome when patients
were divided according to etiology (x2 = 4.274, p = 0.000), with a
better outcome being observed in epileptic SE and toxic SE
patients, and a worse outcome in anoxic SE patients. As expected, a
signiﬁcant difference was observed between the different treat-
ment protocols (x2 = 2.332, p = 0.001), with those responding to
protocol 1 having a better outcome than those requiring protocols
3 and 4.
4. Discussion
There is no universally accepted deﬁnition of SE in clinical
studies. Traditionally, a diagnosis of SE, when convulsive, is based
upon clinical evidence of repeated, clustering seizures, and may be
easier to make than in the absence of clinical signs.11 Indeed, when
SE is non-convulsive, EEG-based evidence of epileptic activity is
required to conﬁrm a diagnosis that may only be suspected on the
basis of clinical ﬁndings.10 Therefore, when EEG is not available,
NCSE may be suspected, though not conﬁrmed, which highlights
the importance of the role played by EEG in the diagnosis and
management of SE.
The diagnosis-related problems (i.e. clinical vs electro-clinical)
may hamper the interpretation and comparison of results from
different studies, since diagnostic criteria are not homogeneous. In
our study, we characterized SE according to both its clinical
presentation (convulsive or non-convulsive) and to the EEG
ﬁndings (focal or generalized). Our data based on a clinical and
electro-clinical evaluation conﬁrm the widespread observation
that clinically convulsive SE and patients with focal EEG alterations
are older than those with non-convulsive SE and generalized EEG
abnormalities. This observation is probably related to the etiology:
brain damage (stroke or brain tumors) that induces ‘‘lesional’’ SE is
typical of older patients. By contrast, patients with anoxic SE,
generally secondary to cardiac arrest, and toxic dysmetabolic SE
are generally younger than patients with brain lesions. As
expected, epileptic subjects presenting a SE represented the
youngest group of patients.
SE is usually characterized by a signiﬁcant short-term
morbidity and mortality. Moreover, since SE is a neurological
emergency, patient institutionalization and prompt medical
treatment is recommended.2,18 Although there is a large consensus
for an aggressive treatment of generalized convulsive SE,
agreement is lacking as to what the proper management of NCSE
should consist of.20,21 International guidelines for convulsive SE
management suggest that benzodiazepines and phenytoin should
be used as ﬁrst- and second-line treatments, though the authors of
some studies22 have pointed out that as many as 35–45% of
patients with SE may be unresponsive to these approaches.However, it should be borne in mind that SE in those studies was
considered in general terms, there being no distinction between
the convulsive and non-convulsive types or the different etiologies.
In our patients, we observed a difference in the response to
treatment only when SE was considered according to the EEG
ﬁndings and etiology: protocol 1 (i.v. benzodiazepines) proved to
more effectively control focal SE, which is more often observed in
patients with a lesional or epileptic etiology. On the other hand, a
more aggressive approach, requiring combined treatments or
sedation in intensive care units, was required in anoxic patients,
which probably reﬂects the more complex cardiovascular insta-
bility of such patients.
As regards outcome, it should be borne in mind that the
underlying condition inducing the SE, rather than SE itself, may be
the main reason for the high mortality rate, which is approximately
20%.14 Previous studies have shown that older age and acute
symptomatic etiology are related to the worst outcomes.15 In this
regard, a prognostic score (Status Epilepticus Severity Score –
STESS) that takes into account age > 65 years, previous history of
seizures, seizure type and extent of consciousness impairment has
recently been proposed as an outcome measure in clinical
practice.17
Our study conﬁrms the role of age in SE prognosis; interestingly,
only a trend toward a signiﬁcantly poorer prognosis emerged when
age was considered as a continuous variable. This ﬁnding may be
ascribed to the fact that the prognosis of SE is more closely related
to its etiology than to the SE itself. To sum up, the prognosis was
best in patients with CSE, particularly those with focal SE, in whom
the etiology was epileptic or toxic and who only received ﬁrst-line
treatment, regardless of their age and gender. Previous studies
have shown that myoclonic SE in anoxic encephalopathy is
associated with a poor outcome and that treatment of SE does not
generally inﬂuence the prognosis.16 In our patients, more intensive
treatment was associated with a poor outcome owing to the
severity of the clinical conditions: the outcome in patients who
responded to protocol 1 was better than that in patients who
received protocols 3 and 4. This is, however, to be expected given
that the clinical conditions of patients who require multiple
aggressive approaches are evidently more complex.
5. Conclusions
The accurate characterization of SE is fundamental. A prompt
neurophysiological EEG evaluation with continuous EEG monitor-
ing, when available, combined with a clinical evaluation helps to
make an accurate prognosis and select the most appropriate
therapy. In lesional and epileptic SE, ﬁrst-line treatments and
subsequent periodical standard EEG may be sufﬁcient to control
the electro-clinical status, while intensive care unit management
with a more aggressive therapeutic approach and continuous EEG
monitoring are recommended for refractory SE.
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